# US 2022/0137027 A1 · Method for evaluating molecular changes related to a molecule effect in a biological sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0137027 A1
- Document ID: US20220137027A1
- Status: Published application
- Kind: A1
- Application number: 17/424,509
- Filed: 2020-01-21
- Published: 2022-05-05
- Earliest claimed: 2019-01-22
- Assignees: Imabiotech
- Applicants: Imabiotech
- Inventors: JONATHAN STAUBER; RIMA AIT-BELKACEM; DAVID BONNEL; FABIEN PAMELARD
- Web page: https://patentgrep.com/patent/US20220137027A1

## CPC

- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G06T 7/0012: {Biomedical image inspection}
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G06T 2207/10004: Still image; Photographic image
- G06T 2207/30096: Tumor; Lesion
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL

## Abstract

The present invention relates to a method for ex-vivo or in-vitro evaluation of an effect of a molecule of interest on at least one molecular marker in a dosed biological sample. The method of the invention is based on the segmentation of a biological sample based on the concentration of a molecule of interest and the comparison of molecular changes associated to the presence of the molecule of interest within different parts/segments of a same biological sample or between different biological samples, which may comprise different amounts of said molecule of interest and/or different molecules of interest.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for ex-vivo or in-vitro evaluation of an effect of at least one molecule of interest on at least one molecular marker in a dosed biological sample comprising:
selecting a dosed biological sample, which has been previously exposed to said at least one molecule of interest;
detecting the presence of the at least one molecule of interest in the dosed biological sample with a molecular imaging method and obtaining a molecular map of the dosed biological sample for the at least one molecule of interest;
spatially segmenting the molecular map of the dosed biological sample as a function of spectral information to obtain a segmentation map of the at least one molecule of interest in the dosed biological sample;
selecting a first region of interest (ROI) from the segmentation map, said first ROI having a first intensity for the at least one molecule of interest;
measuring the intensity or quantity of at least one molecular marker in said first ROI;
comparing the intensity or quantity of at least one molecular marker in the first ROI with the intensity or quantity of at least one molecular marker in a second ROI, said second ROI being selected from the dosed biological sample or from another biological sample.

### Claim 17 (depends on 16)

The method of claim 16, wherein the biological sample is selected from the group consisting of a tissue sample, organoids, and a biological fluid sample.

### Claim 18 (depends on 16)

The method of claim 16, wherein the dosed biological sample is a tissue section which has been obtained by previously sampling an animal which has been previously administered by the molecule of interest, or wherein the dosed biological sample has been contacted in vitro with the molecule of interest.

### Claim 19 (depends on 16)

The method of claim 16, wherein the molecular imaging method is selected from Mill imaging, PET imaging, CT imaging, IF, ISH, IHC, mass spectrometry or cytometry imaging.

### Claim 20 (depends on 16)

The method of claim 16, wherein the molecule of interest is a candidate molecule and the dosed biological sample has been previously obtained by sampling in an animal that has been previously administered with the candidate molecule.

### Claim 21 (depends on 16)

The method of claim 16, wherein the second ROI is selected from the segmentation map of the dosed biological sample, said second ROI being physically different from the first ROI and having a second intensity for the molecule of interest.

### Claim 22 (depends on 16)

The method of claim 16, wherein the second ROI is selected from a second biological sample which has not been previously exposed to the molecule of interest, said second biological sample being from same biological origin as the dosed biological sample, and wherein optionally the comparison between the first and second ROI allows to identify at least one biological marker specific to the molecule of interest.

### Claim 23 (depends on 16)

The method of claim 16, wherein the second ROI is selected from a second biological sample, which has been previously exposed to the molecule of interest at a dose concentration different from the dose concentration for the dosed biological sample, said second biological sample being from same biological origin as the dosed biological sample.

### Claim 24 (depends on 16)

The method of claim 16, wherein the second ROI is selected from a second biological sample which has been previously exposed to a second molecule of interest, said second biological sample being from same biological origin as the dosed biological sample.

### Claim 25 (depends on 24)

The method of claim 24, wherein the molecules of interest are two distinct candidate molecules, the comparison between the first ROI and the second ROI allows to discriminate between said candidate molecules.

### Claim 26 (depends on 24)

The method of claim 24, for evaluating and comparing the effect of at least two different molecules of interest on at least one molecular marker.

### Claim 27 (depends on 16)

The method of claim 16, wherein the measure of the quantity or intensity of the biological marker in the first ROI and/or the second ROI is performed with a molecular imaging method and/or wherein the measure of the quantity or intensity of the biological marker in the first ROI and/or the second ROI is performed by bioanalysis.

### Claim 28 (depends on 16)

The method of claim 16, wherein the ROI is extracted from the biological sample by laser capture microdissection, and wherein the ROI is optionally cultivated in a culture medium before performing the bioanalysis.

### Claim 29 (depends on 28)

The method of claim 28, wherein an effect of the molecule of interest is evaluated by comparing gene or transcripts expression, lipidomics, peptidomics, proteomics and/or metabolics changes between the first and the second ROI.

### Claim 30 (depends on 16)

The method of claim 16, wherein the molecule of interest is a therapeutic antibody, and wherein the presence of said therapeutic antibody is detected by contacting the biological sample with a marked antibody anti-therapeutic antibody.

### Claim 31 (depends on 19)

The method of claim 19, wherein the molecular imaging method and is selected from MALDI, DESI, LESA, LA-ICP-MS or SIMS.

### Claim 32 (depends on 27)

The method of claim 27, wherein the molecular imaging method is selected from MSI, ISH, IF, IHC, MRI, imaging mass cytometry, CT or PET imaging.

### Claim 33 (depends on 27)

The method of claim 27, wherein the bioanalysis is performed by mass spectrometry, electrophoresis, ligand binding assay, nuclear magnetic resonance, microdialysis and chromatography, magnetic bead multiplex immunoassay or ELISA.

### Claim 34 (depends on 17)

The method of claim 17, wherein the biological sample is a urine sample, plasma sample, cerebrospinal fluid, or a cell suspension.
